INCY — INCYTE CORP
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 879169 ·
Last close
$103.23
Market Cap
$20.62B
52W High
$106.37
52W Low
$89.25
ADV30
1,604,470
Next earnings
2026-07-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,272,676,000 | 1,168,176,000 | 324,173,000 | 303,330,000 | 7,339,113,000 | 3,461,114,000 | 1,716,266,000 |
| Dec 2025 | 1,506,835,000 | 1,385,735,000 | 383,963,000 | 299,279,000 | 6,957,973,000 | 3,097,817,000 | 1,790,495,000 |
| Sep 2025 | 1,365,980,000 | 1,266,980,000 | 431,296,000 | 424,169,000 | 6,330,356,000 | 2,455,006,000 | 1,679,162,000 |
| Jun 2025 | 1,215,529,000 | 1,136,729,000 | 310,812,000 | 404,999,000 | 5,821,354,000 | 1,954,969,000 | 1,650,451,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,516,782,000
Investing CF
$-191,910,000
Financing CF
$198,537,000
CapEx
$-95,898,000
Dividends Paid
—
Buybacks
$-103,000
EPS Diluted TTM
$7.08
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$517,099,000
Inventory
$115,624,000
Receivables
$1,051,499,000
ST Investments
$554,711,000
EBIT TTM
$1,776,198,000
Pretax Income TTM
$1,773,861,000
Interest Exp TTM
$2,337,000
Analysts
22
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,361,019,904
EBITDA
$1,548,935,040
Free Cash Flow
$558,867,008
Enterprise Value
$16,129,681,408
Total Cash
$4,015,824,896
Total Debt
$39,430,000
Shares Out
199,782,155
Trailing EPS
$7.08
Book Value
$28.12
ROE
30.8%
ROA
13.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 5,141,242,000 | 1,342,790,000 | 1,286,650,000 | 6,957,973,000 | 1,790,495,000 | — | 1,413,498,000 |
| Dec 2024 | 4,241,217,000 | 101,294,000 | 32,615,000 | 5,444,322,000 | 1,996,694,000 | — | 335,337,000 |
| Dec 2023 | 3,695,649,000 | 655,358,000 | 597,599,000 | 6,782,107,000 | 1,592,270,000 | — | 496,487,000 |
| Dec 2022 | 3,394,635,000 | 591,626,000 | 340,660,000 | 5,840,984,000 | 1,470,865,000 | — | 969,941,000 |
TTM Snapshot
Revenues TTM
$3,693,186,000
NetIncome TTM
$572,239,000
OpCashFlow TTM
$0
Assets (Latest)
$5,444,322,000
Forward EPS
$9.11
Max Pain — expiry 2026-06-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $90.00 · spot: $103.23 · call volume: 518 · put volume: 104
Expected Move to 2026-06-18:
±$9.82
(9.51%) —
implied range
$93.41 –
$113.05
· ATM straddle on $105.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IQV | IQVIA HOLDINGS INC. | $31.09B | $186.25 | — |
| MEDP | Medpace Holdings, Inc. | $13.33B | $466.79 | — |
| ICLR | ICON PLC | $11.62B | $151.82 | — |
| IDXX | IDEXX LABORATORIES INC /DE | $45.66B | $578.89 | — |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $9.14B | $189.85 | — |
News headlines (Yahoo Finance, 1h cache)
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B
2026-06-09 19:30 · Yahoo
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results
2026-06-09 13:29 · Yahoo
Sector Update: Healthcare Stocks Decline Late Afternoon
2026-06-08 19:48 · Yahoo
Incyte To Acquire Vega Therapeutics For Up To $2 Billion
2026-06-08 13:52 · Yahoo
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
2026-06-08 11:16 · Yahoo
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
2026-06-08 11:00 · Yahoo
Adma Biologics (ADMA) Down 5.8% Since Last Earnings Report: Can It Rebound?
2026-06-05 15:30 · Yahoo
AbCellera Appoints Dr. Victor Sandor to its Board of Directors
2026-06-05 13:00 · Yahoo
Is Tafasitamab’s First-Line DLBCL Win Reframing The Investment Case For Incyte (INCY)?
2026-06-05 12:06 · Yahoo
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
2026-06-04 12:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.